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In community studies, both attenuated psychotic symptoms (APS) and basic symptoms
(BS) were more frequent but less clinically relevant in children and adolescents compared
to adults. In doing so, they displayed differential age thresholds that were around age 16
for APS, around age 18 for perceptive BS, and within the early twenties for cognitive
BS. Only the age effect has previously been studied and replicated in clinical samples
for APS. Thus, we examined the reported age effect on and age thresholds of 14
criteria-relevant BS in a patient sample at clinical-high risk of psychosis (N = 261, age
15–40 yrs.), recruited within the European multicenter PRONIA-study. BS and the BS
criteria, “Cognitive Disturbances” (COGDIS) and “Cognitive-perceptive BS” (COPER),
were assessed with the “Schizophrenia Proneness Instrument, Adult version” (SPI-A).
Using logistic regressions, prevalence rates of perceptive and cognitive BS, and of
COGDIS and COPER, as well as the impact of social and role functioning on the
association between age and BS were studied in three age groups (15–18 years, 19–23
years, 24–40 years). Most patients (91.2%) reported any BS, 55.9% any perceptive and
87.4% any cognitive BS. Furthermore, 56.3% met COGDIS and 80.5% COPER. Not
exhibiting the reported differential age thresholds, both perceptive and cognitive BS, and,
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at trend level only, COPER were less prevalent in the oldest age group (24–40 years);
COGDIS was most frequent in the youngest group (15–18 years). Functional deficits did
not better explain the association with age, particularly in perceptive BS and cognitive
BS meeting the frequency requirement of BS criteria. Our findings broadly confirmed
an age threshold in BS and, thus, the earlier assumed link between presence of BS
and brain maturation processes. Yet, age thresholds of perceptive and cognitive BS did
not differ. This lack of differential age thresholds might be due to more pronounced the
brain abnormalities in this clinical sample compared to earlier community samples. These
might have also shown in more frequently occurring and persistent BS that, however,
also resulted from a sampling toward these, i.e., toward COGDIS. Future studies should
address the neurobiological basis of CHR criteria in relation to age.
Keywords: psychosis, clinical high risk, basic symptoms, age, brain maturation
INTRODUCTION
Despite their low lifetime prevalence of between 0.2 and 3.5%
(1), schizophrenia-spectrum and other psychotic disorders are
among the most severe and costly neuropsychiatric diseases (2–
4). Schizophrenia is the 9th most important cause for disability-
adjusted life-years (DALYs) already in 10–14-year-old boys, and
the 2nd most important in all 15–19-year-olds (5), although full-
blown psychoses rarely manifest in children and adolescents (6).
However, because the majority of psychoses develop slowly over
several years, their first prodromal symptoms will frequently
show in childhood and adolescence; and prodromes with such
an early onset tend to be longer and to be associated with
poorer outcome (7, 8). Thus, the early detection and prevention
of psychosis, which aims to reduce the burden of the disorder
(9–11), has increasingly moved from adult patients into ever
younger patient groups. However, this has been done without
full consideration of potentially influential developmental issues
(6, 12, 13).
In the early detection of psychoses, two complementary
approaches to define the clinical high-risk (CHR) state for
psychosis are currently followed (9, 14). One is the ultra-high-
risk (UHR) approach that was developed to detect an imminent
risk of psychosis. It includes (1) the attenuated psychotic
symptoms (APS) syndrome characterized by recently developed
or worsened symptoms that resemble positive symptoms of
psychosis, yet with still some insight being maintained; (2) the
brief limited intermittent psychotic symptoms (BLIPS) syndrome
with frank positive psychotic symptoms that spontaneously remit
within a couple of days; and (3) the genetic risk plus functional
decline (GRFD) syndrome that combines a significant recent
functional decline with a genetic risk factor of psychosis, i.e., a
first-degree relative with psychosis or a schizotypal personality
disorder in the patient (9, 14).
The second approach is the basic symptoms (BS) approach
that was developed to detect emerging psychosis as early
as possible (9, 14). It includes two alternative criteria,
“Cognitive disturbances” (COGDIS) and “Cognitive-perceptive
BS” (COPER) (Table 1). BS have been described as the earliest
subtle and subjectively experienced symptoms of psychosis
(16–19). BS are subclinical disturbances in the affected
individual’s own mental processes, such as thinking, speech,
(body) perception, motor action, drive, affect, and stress
tolerance, that are primarily recognized by the affected individual
and are only rarely directly observable by others (16–19). BS
were named “basic” as they had been assumed to be “substrate-
close,” i.e., the most immediate psychopathological expression of
the neurobiological aberrations underlying the development of
psychotic disorders. At this, BS are assumed to be the basis on
TABLE 1 | Basic Symptom (BS) criteria.
Cognitive disturbances (COGDIS)
Presence of ≥ 2 of the following 9 basic symptoms of at least moderate severity
(≥3)a within the last 3 months
Inability to divide attention
Thought interference
Thought pressure
Thought blockages
Disturbance of receptive speech
Disturbance of expressive speech
Unstable ideas of reference
Disturbance of abstract thinking
Captivation of attention by details of the visual field
Cognitive-perceptive basic symptoms (COPER)
Presence of ≥ 1 of the following 10 basic symptoms of at least moderate severity
(≥3)a within the last 3 month and first occurrence ≥12 months ago
Thought interference
Thought perseveration
Thought pressure
Thought blockages
Disturbance of receptive speech
Decreased ability to discriminate between ideas/perception, fantasy/true
memories
Unstable ideas of reference
Derealization
Visual perception disturbances (excl. blurred vision and hypersensitivity to light)
Acoustic perception disturbances (excl. hypersensitivity to sound/noises)
aAssessed by the Schizophrenia Proneness Instrument (SPI-A) (15).
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which (attenuated) psychotic symptoms develop as a result of
dysfunctional coping (16, 18). By definition, BS are experienced
with immediate and full insight and, thus, are distinct from APS,
BLIPS and frank psychotic symptoms, which, at least initially, are
experienced as being real and/or reasonable (10, 16, 17, 19).
As a result of the above, models of the early course of
psychosis commonly assume that BS and BS criteria develop first,
and are followed by UHR symptoms and criteria before more
persistent psychotic symptoms set in (9, 10, 14, 16, 17). This
sequence, however, was only partially supported by retrospective
analyses of first-episode psychosis patients (7, 20). However, the
temporal sequence ‘BS-APS-positive symptoms’ was particularly
frequent in first-episode psychosis patients with an onset of first
prodromal symptoms before age 18 (7).
UHR and BS criteria have been associated with pooled long-
term conversion rates into full-blown psychosis between 37
and 61%, with higher conversion rates in BS-defined samples
compared to UHR samples at observation periods of three or
more years, and with significantly lower conversion rates in child
and adolescent compared to adult samples (14). Next to this
lower psychosis-predictive value of CHR criteria in children and
younger adolescents, in particular of the APS syndrome (14,
21), accumulating evidence suggests that age and developmental
aspects might also alter the general clinical relevance and the
prevalence rate of CHR symptoms. Again, this evidence has
mainly accumulated for APS and BLIPS (13, 14, 21–28), in doing
so indicating an age threshold around the age of 16 below which
these symptoms are more frequent, but less clinically relevant in
terms of their association with functional deficits and/or non-
psychotic mental disorder, and less psychosis-predictive (21–
23, 28, 29). In doing so, the interaction of APS with age played
a particular role in predicting psychosocial functioning, with
APS being increasingly associated with functional deficits with
advancing age in the community (29). The only exception was
disorganized communication at APS-level for that, in interaction
with age, no stable association with functional deficits was
revealed. Non-psychotic mental disorders, however, were mainly
predicted independently by female sex and presence of APS (29).
Again, disorganized communication was an exception in that it
predicted mental disorder by its interaction with age rather than
its sole presence. In doing so, participants without disorganized
communication were commonly younger than those with it;
this age effect being more pronounced in those with mental
disorder (29).
As regards BS and BS criteria, the impact of age and
developmental aspects has been less studied. Two studies on the
dimensions of BS indicated differences between children and
adolescents, and adult patients (19, 30). Yet, only one Swiss
community study has so far studied age effects on the prevalence
and clinical relevance of BS (29, 31). It reported age thresholds
of around 18 years of age for perceptive BS and of within the
first half of the twenties for cognitive BS, indicating a higher
prevalence and a lesser clinical relevance, i.e., a lesser association
with functional impairment, below these age thresholds (29, 31).
As in APS, age played a major role in moderating the association
between BS and functional deficits, while female sex was an
independent predictor of mental disorder (29). In doing so, the
association of BS and psychosocial functioning increased with
age. Only in case of perceptual BS, their interaction with age
was additionally moderated by sex, indicating that the effect of
the interaction between age and perceptual BS on psychosocial
impairment was more pronounced in males (29). In case of non-
psychotic mental disorders, in addition to the general sex effect,
age only moderated the effect of cognitive BS, indicating that a
mental disorder was less likely when participants with cognitive
BS were younger (29). Thus, in both APS and BS, age commonly
moderated their association with functional deficits but not their
association with mental disorder (29).
In light of current models and the assumed sequence of BS
before UHR symptoms in the at-risk or prodromal stage of
psychosis (9, 10, 14, 16, 17), the higher age thresholds of BS
(31) compared to APS (22) in the Swiss community study were
surprising, because a lower or at least similar age threshold
of BS compared to APS had been expected (31). Yet, the two
age thresholds of perceptive and cognitive BS seemed to follow
known brain maturation processes (29, 31). Consequently, the
higher prevalence of BS below these thresholds in concert with
the fact that BS mostly occurred too infrequently to meet the
BS criteria’s frequency requirement of “at least once per week”
(Table 1) was explained by ongoing brain maturation processes
(31). According to the suggested model (Figure 1), the prevalent
yet rarely occurring BS below the respective age thresholds
were proposed to signal subtle, transient disruptions of mental
processes that occur as part of the ongoing transformations at
the cerebral level, and thus to support the proposed substrate-
closeness of BS (31). The age threshold of APS, however, seemed
to reflect the age at which most cognitive abilities have been
acquired (31, 37). As a result, APS that were more prevalent
below this threshold and also mainly occurred more rarely than
the required frequency of “at least once per week” (22) were
explained as the expression of not yet fully matured cognitive
abilities, including coping strategies, which makes the young
person more prone to develop inadequate explanatory models
(Figure 1) (31).
In light of these considerations that may have major impact
on future research into the neurobiological underpinnings of
symptoms of psychosis (15, 31) and the future development
of both age-adapted early detection and age-adapted early
interventions (6, 12, 31), and in light of the limited studies on
age effects on BS, we investigated the age effects on and age
thresholds of BS in a CHR sample. In line with the replication
of age effects on APS in clinical samples (23, 25), we expected
that age thresholds would follow those earlier reported from the
Swiss community study (29, 31). Additionally, in light of the
moderating effect of age on the association of BS with functional
impairment, which was weaker in younger subjects (29, 31), we
also examined if the effect of age on BS might be influenced by
the presence of functional impairments.
METHODS
Sample
The sample consisted of 261 patients with a CHR state who were
recruited as part of the EU-funded Personalized Prognostic Tools
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FIGURE 1 | Model of the possible relationship between basic symptoms and brain maturation, and between attenuated psychotic symptoms and maturation of
cognitive abilities (31). This model assumes that (A) subtle subclinical disturbances in cognitive and perceptive processes that are phenomenologically identical to
basic symptoms (BS) might occur during childhood and adolescence as infrequent temporary expressions of insignificant passing dysfunctions in the wake of brain
maturation processes (gray-shaded curve). However, if these disturbances, i.e., BS, occur more frequently (i.e., meet the frequency requirements of the BS criteria)
and are persistent (dotted line), they might be a sign of disturbances in brain maturation processes, which, in line with a neurodevelopmental model of psychosis
(32, 33), might predispose to the development of psychosis. A genetic predisposition, childhood adversities or other risk factors (indicated by flashes) including
stressful life-events and cognitions promoting the development of attenuated psychotic symptoms (APS), such as poor coping, externalization biases or poor source
monitoring (34), might further sustain and/or amplify the development and persistence of information processing disturbances. On the other hand, the model assumes
that (B) unusual perceptual experiences or thought contents phenomenologically identical to APS might occur during childhood and early adolescence as an
expression of not yet fully matured cognitive abilities (gray-shaded curve). If their maturation is impaired by risk factors or stressors (flashes) or neurodevelopmental
disturbances in information processing (that might be experienced as BS), APS might persist or progress (dotted line), potentially leading to positive and potentially
benign schizotypal traits (35), an Attenuated Psychosis Syndrome (36), and/or psychosis.
for Early Psychosis Management (PRONIA) study [www.pronia.
eu (38)] at ten early-detection centers in five European countries
between February 2014 and November 2017 (Table 2). In each
center, the study was approved by the local ethics committee,
and all participants or participant’s parents/guardians gave their
written informed consent prior to study inclusion.
The inclusion criteria of the CHR sample were age between
15 and 40 years, sufficient knowledge of the local language, in
which the assessments were conducted, and meeting any one
of the slightly adapted UHR criteria (Supplementary Table 1)
and/or COGDIS (Table 1). Participants were excluded in case of
a past or present diagnosis of psychosis and of treatment with
any antipsychotic medication at or above the minimum dosage
threshold defined by the DGPPN S3 Guidelines for the treatment
of first-episode psychosis (2006) (39) for either more than 30
days or within the past 3 months before baseline assessment
(Supplementary Table 2). Further exclusion criteria were an IQ
below 70, alcohol or polysubstance dependence within the past 6
months, current or past head trauma with loss of consciousness
for more than 5min, or any neurological or somatic disorder
having a potential effect on the brain.
Assessments
For the assessment of the UHR criteria, the Structured
Interview for Psychosis-Risk Syndromes (SIPS) (40) was used.
The BS criteria COPER and COGDIS were assessed with the
Schizophrenia Proneness Instrument – Adult version (SPI-A)
(41). Following the procedures of the Swiss community study
(22, 23, 31), cognitive and perceptive BS were distinguished:
Cognitive BS comprised at least any one of the following 12
BS: inability to divide attention; thought interference, pressure,
blockages and perseveration; disturbances of receptive and
expressive speech, of abstract thinking, or of discriminating
between ideas and perceptions; unstable ideas of reference;
capturing of attention by details of the visual field and
derealization. Perceptive BS included at least any one of the
various visual or acoustic perception disturbances. Additionally,
BS were distinguished according to meeting or not meeting
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TABLE 2 | Sociodemographic characteristics and prevalence of at least one of the 14 basic symptom (BS), irrespective of BS criteria’s frequency and novelty
requirements.
Characteristic Subjects with ≥ 1 of
14 BS (n = 238)
Subjects without any
of 14 BS (n = 23)
Total sample
(n = 261)
Statisticsa
Mdn Mean (SD) Mdn Mean (SD) Mdn Mean (SD) U p ES
Age 21.5 23.0 (± 5.3) 26.0 25.0 (± 6.4) 22.0 23.3 (± 5.5) 1,934.5 0.020 0.144
Educational years 13.0 13.5 (± 2.7) 14.0 13.9 (± 3.1) 13.0 13.5 (± 2.7) 1,299.5 0.253 0.076
N % N % N % x2 df p ES
Age group (n) 5.087 2 0.079 0.140
15–18 yrs. 40 95.2b 2 4.8b 42 16.1b
19–23 yrs. 110 94.0b 7 6.0b 117 44.8b
24-40 yrs. 88 86.3b 14 13.7b 102 39.1b
Center 8.280 9 0.506 0.178
LMU Munich 83 34.9 11 47.8 94 36.0 1.527 1 0.217 0.076
UBS Basel 23 9.7 0 0.0 23 8.8 2.437 1 0.118 0.097
UKK Cologne 34 14.3 3 13.0 37 14.2 0.027 1 0.870 0.010
University Birmingham 16 6.7 2 8.7 18 6.9 0.127 1 0.721 0.022
University Turku 27 11.3 0 0.0 27 10.3 2.910 1 0.088 0.106
University Udine 17 7.1 3 13.0 20 7.7 1.032 1 0.310 0.063
University Milan 20 8.4 2 8.7 22 8.4 0.002 1 0.962 0.003
University Münster 11 4.6 2 8.7 13 5.0 0.735 1 0.391 0.053
University Bari 1 0.4 0 0.0 1 0.4 0.097 1 0.755 0.019
University Düsseldorf 6 2.5 0 0.0 6 2.3 0.593 1 0.441 0.048
Gender: male 114 47.9 10 43.5 124 47.5 0.164 1 0.685 0.025
Migratory backgroundc 28 11.8 2 8.7 30 11.5 0.194 1 0.659 0.027
Any current non-psychotic axis-I disorder 151 63.4 8 34.8 159 60.9 7.237 1 0.007 0.167
Any major depressive disorder 117 49.2 5 21.7 122 46.7 6.335 1 0.012 0.156
1st-degree biological relative with psychosis 36 15.1 1 4.3 37 14.2 2.003 1 0.157 0.088
Schizotypal personality disorder 17 7.1 2 8.7 19 7.3 0.075 1 0.784 0.017
Any UHR-criterion 172 72.8 15 65.2 187 71.6 0.513 1 0.474 0.044
BLIPS syndrome 5 2.1 0 0.0 5 1.9 0.493 1 0.483 0.043
APS syndrome 154 64.7 13 56.5 167 64.0 0.610 1 0.435 0.048
GRFD syndrome 36 15.1 3 13.0 39 14.9 0.072 1 0.789 0.017
COGDIS 147 61.8 0 0.0 147 56.3 32.523 1 0.001 0.353
COPER 210 88.2 0 0.0 210 80.5 103.858 1 0.001 0.631
impaired GF sociald ≤ 6 122 51.3 8 34.8 130 49.8 2.278 1 0.131 0.093
impaired GF rolee ≤ 6 130 54.6 13 56.5 143 54.8 0.031 1 0.861 0.011
aTest statistics: Mann-Whitney U-test for non-normally distributed continuous variables with Rosenthal’s r as effect size (ES), chi-squared test for categorical variables with Cramer’s V
as effect size (ES).
b% of age group not of BS group sample.
cany other white/Asian/black/mixed background.
dGF social = Global Functioning social scale a value of ≤ 6 indicates presence of “moderate impairment in social/interpersonal functioning.”
eGF role = Global Functioning (GF) role scale a value of ≤ 6 indicates presence of “moderate impairment of role functioning.”
the novelty requirement (i.e., BS constitutes a disruption in
the person’s “normal” self and has a distinct time of first
occurrence) and the frequency requirement (i.e., BS occurs
at least once per week within the past 3 months) of the
BS criteria.
Furthermore, the Structured Clinical Interview for DSM-IV-
TR (SCID) (42) was performed to rule out past or present
psychosis and to assess other mental disorders. Moreover, the
Global Functioning: Social (GF: S) (43) and Global Functioning:
Role (GF: R) (43) as well as the Global Assessment of Functioning
(GAF) (44) were used to measure level of psychosocial
functioning both globally and specifically. Impaired psychosocial
functioning was assumed when the global GAF score was 70 or
lower and when a GF score was 6 or lower.
All interviewers were trained in the assessments. Additionally,
weekly supervision within each research center and monthly
CHR case conferences on the CHR criteria relevant for inclusion
by phone with an expert in early detection of psychoses (F.S.-L.)
were carried out to ensure excellent and reliable data quality
across centers.
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Statistical Analyses
Using SPSS 25.0, frequencies were compared by chi-squared test
for categorical variables, and non-normally distributed interval
and ordinal data were analyzed with the Mann-Whitney U test.
As in previous studies of age effects (22, 23, 29, 31), binary
logistic regression analysis with “enter” as method were used
to evaluate effects of defined age ranges on prevalence rates of
“at least any one of the 14 BS,” “at least any one cognitive BS”
and “at least any one perceptive BS” as well as of the related
novelty and frequency requirements in the total CHR sample
(N = 261). Because our age range differed from earlier studies
(22, 23, 29, 31) by not including the age range of 8–14 years, we
aligned the definition of our age groups with the results on BS
in the community (29, 31) and defined three age groups: 15–18
years for the age threshold around age 18 reported for perceptive
BS, 19–23 years because of the age threshold of within the first
half of the twenties reported for cognitive BS, and 24–40 years.
Also roughly in line with the previous studies (22, 23, 31), the
age group of 19–23 years was used as the reference group in
regression analyses. This age group was chosen, because the peak
onset of first-episode psychosis was reported to be between the
ages of 20 and 24 years (45) and, thus, this age group can be
expected to show the highest rate of CHR symptoms and criteria.
The reliability of the regression results was internally examined
using bootstrapping (N = 1,000).
Furthermore, stepwise logistic regression analyses (Wald
method) were employed to test effects of age and of functional
deficits in both social and role functioning as well as of
their interaction on the respective presence of BS and the
BS criteria requirements. More specifically, “age group,” “GF:
S ≤ 6” or “GF: R ≤ 6” and “age group” × “GF: S ≤
6”/”GF: R ≤ 6” were entered as potential predictors and the
respective BS variable entered as dependent variable. To ensure
stable results, the effects were only considered as significant
when the same predictors were selected in both forward and
backward selection.
RESULTS
Presence of at least one of the 14 BS within 3 months prior to
the interview was reported by 238 patients (91.2%) (Table 2).
Out of these, 87.4 % reported cognitive BS and 55.9 % reported
perceptive BS. Furthermore, the COGDIS criterion was met by
147 (56.3%) and the COPER criterion by 210 patients (80.5%);
naturally, all of them were members of the group with BS
(Table 2). Any UHR criterion was reported by 187 participants
(71.6%), mainly by meeting the APS syndrome (64.0%). There
was no difference in frequency of UHR criteria between those
with and without BS. Patients with BS were on average 2
years younger than those without any BS and more frequently
presented with any non-psychotic axis-I disorder, in particular
major depressive disorder (Table 2). No significant difference
was seen between those with and without BS with regard to
educational years, recruitment site, sex, migration background,
family history of psychosis, presence of schizotypal personality
disorder or of functional impairment (Table 2).
Logistic regression analyses indicated a lower frequency for
both perceptive and cognitive BS, and the related requirements,
in those of age 24 and over compared to the two younger
groups, i.e., the 15–18-year-olds and the reference group of 19–
23-year-olds (Table 3). Overall, this age effect was slightly more
pronounced for perceptive BS compared to cognitive BS, with
Odds Ratios [i.e., Exp (ß)] being between 0.073 and 0.004 points
lower. For all 14 BS together, this difference only reached the
level of a statistical trend for overall prevalence and the frequency
requirement (Table 3).
As regards BS criteria, COPER revealed a statistical trend
toward being least frequent in the oldest age group (Table 4).
COGDIS was significantly more frequent in the youngest age
group, i.e., in 15–18-year-olds (Table 4).
Regarding the potential influence of the functional level on
the presence of BS or BS criteria, the results indicated that only
age rather than impaired social or role functioning or their
interaction with age was a predictor of the presence of BS and BS
criteria (Tables 5, 6). Yet, compared to univariate analyses of age
effects, age was less frequently selected as a significant predictor
in the multivariate analyses (Tables 5, 6).
DISCUSSION
This is the first study to examine the effect of age and
developmental aspects in a CHR sample, alternatively defined
by UHR criteria and COGDIS. Within our clinical CHR sample,
91.2% reported the presence of any of the 14 BS included
in the definition of COGDIS and COPER. Expectedly and
largely independent of functional deficits, our analyses showed
a significant lower prevalence of BS in the older age group, i.e.,
in patients of and above age 24, with the relative probability of
reporting BS decreasing by roughly 35–40%.
The previously described age thresholds for perceptive BS
around late adolescence (i.e., around age 18) and for cognitive BS
in the early twenties (31) that seemed to follow brain maturation
processes were considered as further support of the assumption
that BS were the most immediate psychopathological expressions
of neurobiological aberrations underlying the disorder, i.e., that
they were “substrate-close” (29, 31). Hence, the higher prevalence
of usually infrequently occurring BS in younger age groups in
the community was regarded as indicating that low-frequency
BS might occur in childhood and adolescence as an infrequent
and temporary non-pathological expression of insignificant and
transient dysfunctions in the wake of normal brain maturation
(31). Thus, given an undisturbed, “normal” brain maturation,
these non-pathological BS would spontaneously remit – or grow
out again – over the course of further maturation processes (31)
(Figure 1). In the Swiss community sample (31), however, BS had
not only been less frequent than in our sample (18.1 vs. 91.2%),
they had also been reported as meeting frequency requirements
of BS criteria, i.e., as occurring at least once per week, at a far
lower rate (in only 33.7 vs. 90.7% of those with BS). Whereas,
the rate of those meeting the novelty requirement had been only
slightly lower in the community (in 77.8 vs. 98.7% of those with
BS). A higher frequency of BS along with a higher persistence,
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TABLE 3 | Effects of age on the report of the 14 BS irrespective of novelty and frequency (a), when meeting novelty requirement (b) and when meeting frequency
requirement (c); binary logistic analysis with method “enter” and 19–23-year-olds as the reference age group.
Age group (years) ß SE Wald (df = 1) p after bootstrap Exp (ß) 95% CI n present % present
(A) PREVALENCE OF BS IRRESPECTIVE OF NOVELTY AND FREQUENCY
≥ 1 BS (in 19–23 years: n = 110, 94%)
15–18 0.241 0.823 0.086 0.769 1.273 0.25–6.38 40 95.2
24–40 −0.916 0.485 3.577 0.059 0.400 0.16–1.03 88 86.3
≥ 1 cognitive BS (in 19–23 years: n = 107, 91.5%)
15–18 −0.119 0.621 0.037 0.848 0.888 0.26–2.99 38 90.5
24–40 −0.896 0.417 4.612 0.032 0.408 0.18–0.93 83 81.4
≥ 1 perceptive BS (in 19–23 years: n = 77, 65.8%)
15–18 0.147 0.387 0.145 0.703 1.159 0.54–2.47 29 69.0
24–40 −1.093 0.281 15.105 < 0.001 0.335 0.19–0.58 40 39.2
(B) PREVALENCE OF BS MEETING NOVELTY AND IRRESPECTIVE OF FREQUENCY REQUIREMENT
≥ 1 BS (in 19–23 years: n = 109, 93.2%)
15–18 0.384 0.812 0.223 0.636 1.468 0.3–7.20 40 95.2
24–40 −0.930 0.456 4.153 0.042 0.394 0.16–0.97 86 84.3
≥ 1 cognitive BS (in 19–23 years: n = 104, 88.9%)
15–18 −0.078 0.56 0.019 0.889 0.925 0.31–2.78 37 88.1
24–40 –0.845 0.378 5.010 0.025 0.429 0.21–0.90 79 77.5
≥ 1 perceptive BS (in 19–23 years: n = 75, 64.1%)
15–18 0.223 0.385 0.333 0.564 1.249 0.59–2.66 29 69.0
24–40 –1.018 0.28 13.242 < 0.001 0.361 0.21–0.63 40 39.2
(C) PREVALENCE of BS MEETING FREQUENCY AND IRRESPECTIVE OF NOVELTY REQUIREMENT
≥ 1 BS (in 19–23 years: n = 101, 86.3%)
15–18 0.409 0.591 0.479 0.489 1.505 0.47–4.79 38 90.5
24–40 –0.609 0.359 2.881 0.090 0.544 0.27–1.10 79 77.5
≥ 1 cognitive BS (in 19–23 years: n = 97, 82.9%)
15–18 0.423 0.536 0.621 0.431 1.526 0.53–4,36 37 88.1
24–40 –0.656 0.329 3.964 0.046 0.519 0.27–0.99 73 71.6
≥ 1 perceptive BS (in 19–23 years: n = 55, 47%)
15–18 0.120 0.360 0.111 0.739 1.127 0.56–2.28 21 50.0
24–40 –0.663 0.283 5.504 0.019 0.515 0.30–0.90 32 31.4
Significant predictors (p < 0.05) are in bold type, predictors with significance at statistical trend (p < 0.10) in bold italics.
TABLE 4 | Effects of age on the report of BS criteria COPER and COGDIS; binary logistic analysis with method “enter” and 19–23-year-olds as the reference age group.
Age group (years) ß SE Wald (df = 1) p after bootstrap Exp (ß) 95% CI N present % present
Cognitive-perceptive BS (COPER; in 19–23 years: n = 98, 93.8%)
15–18 0.151 0.507 0.089 0.766 1.163 0.43-3.14 36 85.7
24–40 –0.568 0.338 2.818 0.093 0.567 0.29–1.1 76 74.5
Cognitive disturbances (COGDIS; in 19–23 years: n = 60, 51.3%)
15–18 0.751 0.382 3.874 0.049 2.119 1.0–4.48 29 69.0
24–40 0.225 0.272 0.682 0.409 1.252 0.73–2.14 58 56.9
Significant predictors (p < 0.05) are in bold type, predictors with significance at statistical trend (p < 0.10) in bold italics.
which had not been examined in both the community and the
present study, has been assumed to indicate disturbances in
brain maturation that might predispose to the development of
psychosis (31) (Figure 1). Consequently, our present results from
a more mentally unwell clinical sample suggest that they might
not exhibit the same differential age thresholds for perceptive and
cognitive BS for the very reason that the frequent occurrence of
BS already signals aberrant neurodevelopment. If this was true,
BS should also be more persistent in clinical samples; thus, the
course of BS needs to be examined in future studies. For this
reason, future psychopathological and neurobiological studies
should not only assess the age-of-onset of BS but also examine
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TABLE 5 | Age effects on BS considering impaired global social functioning (GF social ≤ 6).
Significant predictor ß SE Wald (df = 1) p after bootstrap Exp (ß) 95% CI
Prevalence of BS irrespective of novelty and frequency requirements
≥ 1 BS No significant predictor
≥ 1 cognitive BS No significant predictor
≥ 1 perceptive BS Age –0.684 0.191 12.838 < 0.001 0.505 0.35–0.73
Prevalence of BS meeting novelty irrespective of frequency requirement
≥ 1 BS Age –0.637 0.334 3.633 0.057 0.529 0.28–1.02
≥ 1 cognitive BS No significant predictor
≥ 1 perceptive BS Age –0.664 0.190 12.262 < 0.001 0.515 0.36–0.75
Prevalence of BS meeting frequency irrespective of novelty requirement
≥ 1 BS No significant predictor
≥ 1 cognitive BS Age –0.571 0.241 5.628 0.018 0.565 0.35–0.91
≥ 1 perceptive BS Age –0.403 0.182 4.908 0.027 0.668 0.47–0.96
Prevalence of BS criteria
COPER No significant predictor
COGDIS No significant predictor
Binary logistic analysis with method “forward” and “backward” using the respective BS as dependent variable; Age group, GF social ≤ 6 and “age group x GF social ≤ 6” entered as
predictors. Only stable models are reported (both methods revealed significant effects). Significant predictors (p < 0.05) are in bold type, predictors with significance at statistical trend
(p < 0.10) in bold italics.
TABLE 6 | Age effects on BS considering impaired global role functioning (GF role ≤ 6).
Significant predictor ß SE Wald (df = 1) p after bootstrap Exp (ß) 95% CI
Prevalence of BS irrespective of novelty and frequency requirements
≥ 1 BS No significant predictor
≥ 1 cognitive BS No significant predictor
≥ 1 perceptive BS Age –0.684 0.191 12.838 < 0.001 0.505 0.35–0.73
Prevalence of BS meeting novelty irrespective of frequency requirement
≥ 1 BS Age –0.668 0.340 3.853 0.050 0.513 0.26–1.0
≥ 1 cognitive BS No significant predictor
≥ 1 perceptive BS Age –0.664 0.190 12.262 < 0.001 0.515 0.36–0.75
Prevalence of BS meeting frequency irrespective of novelty requirement
≥ 1 BS No significant predictor
≥ 1 cognitive BS Age –0.571 0.241 5.628 0.018 0.565 0.35–0.91
≥ 1 perceptive BS Age –0.248 0.107 5.389 0.020 0.780 0.63–0.97
Prevalence of BS criteria
COPER No significant predictor
COGDIS No significant predictor
Binary logistic analysis with method “forward” and “backward” using the respective BS as dependent variable; age group, GF role ≤ 6 and “age group x GF role ≤ 6” entered as
predictors. Only stable models are reported (both methods revealed significant effects). Significant predictors (p < 0.05) are in bold type, predictors with significance at statistical trend
(p < 0.10) in bold italics.
differences between subjects with an onset of BS before and
those with an onset after the likely conclusion of major brain
maturation processes in the early twenties.
Furthermore, from the community results it was assumed
that an onset before the early twenties may reflect aberrant
brain maturation, while an onset at an older age may reflect
neurodegenerative processes (31). The possibility to distinguish
between aberrant neurodevelopmental and neurodegenerative
processes might well-impact on the choice of treatment,
for example between neuroprotective and anti-inflammatory
interventions (46–48). Thus, a simple reliable and valid marker
to guide this distinction, such as age-at-onset and course
of BS, might greatly enhance the development of benign
psychopharmacotherapy in CHR states.
Next to the clinical status, sampling differences might have
also caused the missing differential age thresholds, in particular
the selection bias in favor of cognitive BS that meet novelty
and frequency criteria, the more restricted age range of the
PRONIA study with no inclusion of 8–14-year-olds, the low
number of patients below age 19 (16.1%), and the dominance of
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the reference age group of 19–23-year-olds (44.8%). These biases
resulted in low numbers of cases without any BS and without any
cognitive BS and, relatedly, higher standard errors (SE; Table 3)
in the youngest group, which increase the confidence intervals
and the probability (p) to falsely accept the null hypothesis of
equality between the youngest and the reference group. Thus,
from a statistical point of view, the oldest age group that had
a more favorable ratio between positive and negative cases,
offered a higher likelihood to detect differences between age
groups. Compared to cognitive BS, a higher likelihood to detect
differences between age groups was also given for perceptive BS
that are not part of COGDIS (Table 1) and that, consequently,
were not directly influenced by the inclusion criteria. Because
COPER and COGDIS tend to frequently co-occur because of
their shared cognitive BS (49, 50), and our results might reflect
a slightly more “natural” and robust variance in relation to
age in perceptive BS compared to cognitive BS that was thus
maintained in the multivariate models including functional
deficits. In contrast, in the community sample, the perceptive
BS had shown less pronounced age effects as compared to
cognitive BS (31). In light of these differences in sampling and
clinical status between the earlier community (29, 31) and our
clinical sample, the missing difference between the age thresholds
does not seem surprising. Rather, overall, our findings seem to
support the notion that criteria-relevant BS occur more frequent
before the conclusion of brain maturation in the first half of
the twenties. The assumed close link of BS to the “substrate,”
of course, requires validation in future neurobiological studies,
for example in structural imaging studies for that a decrease
in gray matter volume (GMV) would be expected to be related
to BS groups as a result of potential aberrant brain maturation
leading, for example, to an excess in pruning (18, 51, 52) or
to neurodegenerative, for example, inflammatory processes (53,
54). In respect to the model on both BS and UHR symptoms
(Figure 1), however, an increase in GMVwould be expected to be
related to UHR symptoms as a result of excessive compensatory
– though inadequate – neurocognitive coping processes in
response to other symptoms or environmental stressors (34, 55).
Thus, the combined assessment of BS and symptomatic UHR
criteria might help to better understand brain imaging results in
UHR samples reporting both GMV decrease (in the right gyrus
rectus, the right superior frontal gyrus, and the left superior
frontal gyrus) and GMV increase (in the bilateral median
cingulate, the right fusiform gyrus, the left superior temporal
gyrus, and the right thalamus) (56). The GMV-increased primary
auditory and neocortical language regions, superior temporal
gyrus, and insula were reported as the core regions responsible
for the positive symptoms, such as delusions, hallucinations,
and disorganized speech (57–59) and, in longitudinal studies,
progressive GMV reduction of the superior temporal gyrus was
linked to low improvement in positive psychotic symptoms
(60, 61). These GMV increases are still subject to debate and
discussed in relation to different pathophysiological processes
in the early phase, age, other demographic differences, genetic
predisposal, and different MRI scanners or parameters employed
in the method section (56). In light of the model in Figure 1,
however, the increase in regions already related specifically
to positive symptoms might well be perceived as a result
of excessive neurocognitive and psychological processes, i.e.,
intensive cognitive activities, that might have also become
evident by the increase in thalamic structures responsible for the
emotional experience and expression, and cognitive functions,
such as memory, attention, and sensory-guided actions (56).
On the other hand, all three regions with GMV reductions are
involved in cognitive processes that might be reflected by criteria-
relevant cognitive BS (Table 1). These processes are: (1), working
memory (62), possibly impaired in thought blockages; (2)
complex attention (63), possibly impaired in inability to divide
attention and captivation of attention, (3) response inhibition
(64), possibly impaired in thought interference, pressure and
perseveration, disturbance of abstract thinking and unstable ideas
of reference; and (4) language and memory recall (65), possibly
impaired in disturbances of receptive and expressive speech, and
disturbance in distinguish between memory and phantasy. These
possible relations between APS and BS and GMV aberrations
should be studied in future imaging studies using fine-grained
psychopathological measures (15).
Strengths and Limitations
Our study has several strengths and limitations. Among the
strengths are clearly the large sample size and the high-quality
assessment of BS. Next to the discussed limitations related
to sampling, a clear limitation is the related impossibility to
reanalyze the age effect on APS for lack of patients below the
suggested age threshold of 16 years. Yet, this age threshold has
already been replicated in clinical samples (23) and, thus, can be
assumed to work in the present sample. Furthermore, the fact
that the age thresholds in BS reported from the Swiss community
sample (29, 31) could be replicated in this clinical sample, despite
the differences in age range, suggest that these findings may
generalize to other samples.
Outlook
As the early detection of psychosis is increasingly applied to
ever younger age groups, the need to re-evaluate the validity
and clinical significance of current CHR criteria and symptoms
in younger age groups should be addressed in future studies to
improve understanding of what properties (such as age-at-onset,
frequency and persistence) convey their clinical relevance at
different developmental levels. In doing so, their association with
objective measures, such as imaging-based tools, should be given
additional attention to gain further insight into the pathogenesis
of psychosis and its early symptoms. Such studies have the
potential to gain insights into useful targets for interventions
and, thus, to improve outcomes prior to the first manifestation
of psychosis.
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